MabThera/Rituxan

Roche buys cancer company Ignyta for $1.7bn

It has been bolstering its oncology pipeline in particular as three of its top-selling drugs – Avastin, Herceptin and Rituxan – are starting to face biosimilar competition.

Roche's Actemra/RoActemra receives new European approval

Horning said: “By challenging our own MabThera medicine head-to-head, we have been able to set a new standard of care for people with follicular lymphoma. ... with follicular lymphoma who did not respond to or who progressed during or up to six months

AbbVie and Roche plan Venclexta combo filings in leukaemia

MURANO trial shows the duo’s treatment extends PFS. AbbVie and Roche's long-anticipated combination trial of Venclexta/Venclyxto and Rituxan in chronic lymphocytic leukaemia, setting up regulatory filings for ... The phase III MURANO trial pithed the

Sandoz says Humira biosimilar clears clinical hurdle

review of the company's biosimilar version Roche's immunotherapy drug Rituxan (rituximab), another blockbuster with sales of $4bn in the first half of the year.

Roche faces prospect of second Rituxan biosimilar in US

The US Food and Drug Administration (FDA) has started its review of a second biosimilar rival to Roche's blockbuster immunotherapy drug Rituxan, with Novartis' Sandoz unit seeking to dent its ... Rituxan is used to treat blood cancers including

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]